Drug Profile
Vatinoxan - Merck & Co
Alternative Names: L 659066; MK-467Latest Information Update: 16 Oct 1996
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Imidazolidines; Quinolizines; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 24 Nov 1994 Discontinued-Clinical for Diabetes mellitus in USA (Unknown route)